异上腺素在不稳定的第三级心房阻塞期间的有效性和安全性
Manuel De Lazzari1, Nicolò Martini1, Federico Migliore1
1Department of Cardio-Thoraco-Vascular Sciences and Public Health, University Hospital of Padua, Via Giustiniani, 2, 35128 Padua, Italy.
Journal of cardiovascular development and disease
|December 22, 2023
概括
异上腺素有效地管理不稳定的完整心房阻塞,证明比多巴胺更安全,更成功. 这种药物为等待心脏起器植入的患者提供了更好的替代方案.
科学领域:
- 心脏病学 心脏病学
- 紧急医疗 紧急医疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 不稳定的完全心房阻塞是一种危及生命的疾病,在永久心脏起器植入之前需要立即治疗.
- 目前的治疗方法,如通过皮肤进行节拍,可能是痛苦和无效的;推使用阿特罗平,多巴胺或上腺素的药物治疗.
- 异上腺素,尽管有利的形状,没有研究这个指示.
研究的目的:
- 评估与多巴胺相比,异上腺素输注在患有不稳定的第三级心房阻塞的患者中的疗效和安全性.
- 为了确定等待最终心脏起器植入时,异上腺素是否比多巴胺提供更好的临床反应和耐受性.
主要方法:
- 连续一系列患有不稳定的第三级心房阻塞的患者接受了异上腺素或多巴胺输液治疗.
- 排除了无症状或可逆阻塞原因的患者.
- 临床反应的评估是基于症状缓解,血液动力学稳定性,心率和心律的改善,以及没有不良事件.
主要成果:
- 异上腺素输注是安全的,耐受性很好,并没有诱导心律失常或低血压.
- 异上腺素在84%的患者中获得了令人满意的临床反应,明显高于多巴胺 (31%,p < 0.001).
- 与多巴胺相比,异上腺素减少了对临时人工节奏的需求.
结论:
- 异上腺素输注是一种有效和安全的治疗不稳定的第三级心房阻塞在急性设置.
- 与多巴胺相比,异上在这个患者群体中表现出更好的耐受性和临床疗效.
- 异上腺素代表了当前治疗方法的有希望的替代方案,用于在等待心脏起器植入时管理急性心房阻塞.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
747
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
747
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
19
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
19
Adrenergic Antagonists: ɑ and β-Receptor Blockers
453
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
453
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
840
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
840
Depolarizing Blockers: Pharmocokinetics
327
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
327


